Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

Inclusion Criteria: * Diagnosis of stage IV colorectal cancer (histologic proof is not required) * Measurable disease * Spiral CT scan required for both pre- and post-treatment tumor assessments of lesions measuring 1-2 cm * Progressive disease during or within 6 months of most recent prior chemotherapy regimen (bevacizumab, fluoropyrimidine, oxaliplatin, or irinotecan-based treatment) OR considered ineligible for standard therapy * Documentation of submission of tumor material for Kirsten Rat Sarcoma (KRAS) testing available * Prior anti-epidermal growth factor receptor (EGFR) antibody therapy (e.g., cetuximab or panitumumab) required for patients with wild-type KRAS tumor * No known brain metastasis * Patients with neurological symptoms must undergo a CT scan or MRI of the brain to exclude brain metastasis * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Life expectancy ≥ 6 months * Hemoglobin ≥ 9.0 g/dL * Absolute neutrophil count (ANC) ≥ 1,500/mm³ * Platelet count ≥ 100,000/mm³ * White blood cell count (WBC) ≥ 3,400/mm³ * International normalized ratio (INR) \< 1.5 (≤ 3.0 if on anti-coagulation therapy \[e.g., warfarin or heparin\]) * Total bilirubin ≤ 1.5 times upper limit of normal (ULN) * Aspartate aminotransferase (AST) ≤ 2.5 times ULN (≤ 5 times ULN if there is liver involvement) * Alkaline phosphatase ≤ 3 times ULN * Creatinine ≤ 1.5 times ULN * Urine protein:creatinine ratio \< 1 OR urine dipstick \< 2+ OR urine protein \< 1,000 mg by 24-hour urine collection * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for ≥ 6 months after completion of study treatment (≥ 2 weeks after completion of treatment with sorafenib tosylate alone) * Willing to provide mandatory blood samples for translational research studies * Able to swallow whole pills * No inadequately controlled hypertension (i.e., systolic BP \> 150 mm Hg or diastolic BP \> 100 mm Hg on anti-hypertensive medications) * No prior hypertensive crisis or hypertensive encephalopathy * No myocardial infarction or unstable angina within the past 6 months * No congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias * No thrombolic or embolic events (e.g., cerebrovascular accident, including transient ischemic attacks) within the past 6 months * No hemorrhage or bleeding event \> grade 3 within the past 4 weeks * No evidence or history of bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation) * No greater than normal risk of bleeding * No active or recent hemoptysis (≥ ½ teaspoon of bright red blood per episode) within the past 30 days * No concurrent uncontrolled illness including, but not limited to, any of the following: * Ongoing or active infection * Symptomatic congestive heart failure * Unstable angina pectoris * Cardiac arrhythmia requiring anti-arrhythmic drugs * Psychiatric illness or social situations that would limit compliance with study requirements * No known HIV infection or chronic hepatitis B or C infection * No serious, non-healing wound, active ulcer, or untreated bone fracture * Patients with fractures secondary to metastatic disease are eligible after appropriate radiotherapy * No significant traumatic injury within the past 4 weeks * No known or suspected allergy or hypersensitivity to any component of bevacizumab, sorafenib tosylate, or their excipients or to any other agent given in the course of this study * No malabsorption problem * None of the following within the past 6 months: * Significant vascular disease (e.g., aortic aneurysm or aortic dissection) * Peripheral arterial thrombosis * Symptomatic peripheral vascular disease * Abdominal fistula * Gastrointestinal perforation * Intra-abdominal abscess * No other active malignancy within the past 3 years except non melanoma skin cancer or carcinoma in situ of the cervix * Prior malignancy allowed provided patient is not receiving other specific treatment for that malignancy (other than hormonal therapy) * No other concurrent investigational agent for this cancer * Prior radiotherapy allowed * No prior sorafenib tosylate * No prior discontinuation of bevacizumab due to adverse events * More than 4 weeks since prior and no concurrent participation in any other experimental drug study * More than 4 weeks since prior St. John's wort or rifampin * More than 4 weeks since prior and no concurrent major surgical procedure or open biopsy * More than 7 days since prior core biopsy or minor surgical procedure, including placement of a vascular access device * No concurrent anticoagulant, except low-dose warfarin or heparin for deep venous thrombosis prophylaxis